GSK plc announced on March 13, 2026, that the FDA approved its RSV vaccine, Arexvy, for adults aged 18-49 at increased risk, expanding its previous approval for older adults. About 21 million under-50s in the U.S. have risk factors for severe RSV infection, contributing to 17,000 hospitalizations annually.